Pharmaceuticals DC $500K+ Reviewed

BARDA DRIVe Biomedical Innovation & Medical Product Development

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics host-based diagnostics medical countermeasures $500K+

Posted Oct 18, 2022

Due Oct 18, 2027

Description

HHS, through BARDA DRIVe, reissued its EZ-BAA for biomedical innovation and medical product development as EZ-BAA-22-100-SOL-00003. Amendment 001 opens nine areas of interest: ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, and Host-Based Diagnostics; consult the amendment for each area’s details and closing date, and note that this announcement supersedes prior EZ-BAA versions.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

BARDA (Biomedical Advanced Research and Development Authority) under HHS focuses on medical countermeasures, with AOIs explicitly targeting vaccines on demand, digital MCMs, host-directed therapeutics, and host-based diagnostics. These areas directly involve pharmaceuticals, vaccines, diagnostics, and therapeutics for public health emergencies.

View Original Source

Save for Later

Send to Pipeline

Closing date unconfirmed

This bid lists a closing date of Oct 18, 2027, which is more than a year out — almost certainly a data error from the source. Treat the deadline as unknown.

Please confirm the actual deadline on the original source before you rely on it.

Check the source